Despite the smaller number of patients who develop hematological cancers (compared to solid tumors and certain other, non-oncology markets), it is possible to develop and commercialize hematological cancer therapies that become blockbuster drugs (i.e., with sales exceeding $1 billion per year). This research reviews the current market for hematological cancer drugs, including sales data for selected drugs. Also addressed are major challenges and hurdles, in addition to other strategic considerations, such as personalized medicine, that companies in this market must address. Full transcripts of seven interviews with experts in the field of hematological cancers are included in this report.
Hematological cancers arise from and are found in the blood, bone marrow, and lymphatic systems. The first hematological cancer to be identified was Hodgkin?s disease, or Hodgkin lymphoma, in 1832. Since that time, many different hematological cancers have been identified, including the various types of leukemia, lymphoma, and myeloma, plus the myelodysplastic syndromes and myeloproliferative diseases. Altogether, hematological cancers represent a significant medical problem: The American Cancer Society estimated that there would be 140,310 new cases of leukemia, lymphoma, and myeloma, combined, in the United States in 2011, and that 53,010 people would die of these diseases this year.
Published: February 2012
Price: Single User License ? US$2495 ???????????? Corporate User License ? US$9950
?????????????????????????????????????? 
In recent years, newer and more specific therapies for hematological cancers have been developed, such as targeted small-molecule drugs and biological therapies including monoclonal antibodies. However, there remains significant need from a clinical perspective, as well as challenges and opportunities for pharmaceutical companies. This report discusses:
- The different types of hematological cancers, including information about the specific disease, its epidemiology, subtypes and/or staging if appropriate, current therapies, and patient prognosis.
- Pipelines of emerging drugs for treatment of hematological cancers including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative diseases.
- Business and strategic considerations relating to pharmacological therapy for hematological cancers, including assessment of the current market as well as potential markets for emerging new therapies.
- Major challenges and hurdles for companies developing hematological cancer therapies.
- Interviews with experts in the field of hematological cancers, which were conducted exclusively for this report.
A primary focus of this Report is on pipelines of emerging therapies in development for treatment of hematological cancers. Specifically, the clinical development pipelines for leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative diseases are reviewed. Selected emerging therapies that are in Phase II or later stages of development are discussed in the text, while the extensive accompanying tables include these emerging therapies plus many additional earlier-stage therapies that are in development.
Table of Contents
Chapter 1
INTRODUCTION
1.1. Background
1.2. Scope of the Report
Chapter 2
REVIEW OF HEMATOLOGICAL CANCERS (BLOOD CANCERS)
2.1. Leukemia
Acute Lymphocytic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Acute Myelogenous (Myeloid) Leukemia (AML)
Chronic Myelogenous (Myeloid) Leukemia (CML)
Other Types of Leukemia
2.2. Lymphoma
Hodgkin?s Disease
Non-Hodgkin?s Lymphoma (NHL)
2.3. Myeloma
2.4. Myelodysplastic Syndromes (MDS)
2.5. Myeloproliferative Diseases
Chapter 3
CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
3.1. Leukemia
Acute Lymphocytic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)
Acute Myelogenous (Myeloid) Leukemia (AML)
Chronic Myelogenous (Myeloid) Leukemia (CML)
Other Types of Leukemia
3.2. Lymphoma
Hodgkin?s Disease
Non-Hodgkin?s Lymphoma (NHL)
3.3. Myeloma
3.4. Myelodysplastic Syndromes (MDS)
3.5. Myeloproliferative Diseases
Chapter 4
EMERGING THERAPIES FOR LEUKEMIA
4.1. Abbott?s and Genentech/Roche?s Navitoclax
4.2. ARIAD Pharmaceuticals? Ponatinib
4.3. Astellas Pharma?s and Ambit Biosciences? Quizartinib
4.4. AstraZeneca?s AZD1152
4.5. BioCryst Pharmaceutical?s Forodesine
4.6. Boehringer Ingelheim?s Volasertib
4.7. Celator Pharmaceutical?s CPX-351
4.8. Celgene?s REVLIMID
4.9. Chroma Therapeutics? and Cell Therapeutics? Tosedostat
4.10. Clavis Pharma?s Elacytarabine
4.11. Cyclacel Pharmaceuticals? Sapacitabine
4.12. CytRx? Bafetinib
4.13. Eisai?s and Janssen-Cilag?s Dacogen
4.14. EpiCept?s Ceplene
4.15. Genzyme?s/Sanofi?s Clolar
4.16. Gilead Sciences? GS 1101
4.17. GlaxoSmithKline?s ARZERRA
4.18. Medac GmbH?s Treosulfan
4.19. Memgen?s ISF35
4.20. Micromet?s Blinatumomab
4.21. Novartis? Midostaurin
4.22. Pfizer?s Bosutinib
4.23. Roche?s RG7159 (Obinutuzumab)
4.24. Sunesis Pharmaceuticals? Vosaroxin
4.25. Syndax Pharmaceuticals? Entinostat
4.26. Talon Therapeutics? Marqibo
Chapter 5
EMERGING THERAPIES FOR LYMPHOMA
5.1. 4SC AG?s Resminostat
5.2. Abbott?s and Genentech/Roche?s Navitoclax
5.3. Allos Therapeutics? Folotyn
5.4. Astellas Pharma?s YM155
5.5. BioCryst Pharmaceutical?s Forodesine
5.6. Biovest International/Accentia Biopharmaceuticals? BiovaxID
5.7. Celgene?s REVLIMID
5.8. Cell Therapeutics? Pixantrone
5.9. Eli Lilly?s Enzastaurin
5.10. Gilead Sciences? GS 1101
5.11. GlaxoSmithKline?s ARZERRA
5.12. Kyowa Hakko Kirin?s KW-0761
5.13. Memgen?s ISF35
5.14. Novartis? Afinitor
5.15. Novartis? Panobinostat
5.16. Pfizer?s Inotuzumab Ozogamicin
5.17. Pharmacyclics? PCI-32765
5.18. Plexxikon?s (and Daiichi Sankyo?s) PLX3397
5.19. Roche?s RG7159 (Obinutuzumab)
5.20. Sanofi?s SAR245409
5.21. Spectrum Pharmaceuticals? and Topotarget?s Belinostat
5.22. Syndax Pharmaceuticals? Entinostat
5.23. Telik?s TELCYTA
5.24. Teva Pharmaceutical Industries? and CureTech?s CT-011
Chapter 6
EMERGING THERAPIES FOR MYELOMA
6.1. ?terna Zentaris? and Keryx Biopharmaceuticals? Perifosine (KRX-1401)
6.2. Bristol-Myers Squibb?s and Abbott?s Elotuzumab
6.3. Celgene?s Actimid
6.4. Geron?s Imetelstat
6.5. Janssen Biotech?s Siltuximab (CNTO 328)
6.6. Novartis? BHQ880
6.7. Novartis? Panobinostat
6.8. Onyx Pharmaceuticals? Carfilzomib
6.9. PharmaMar?s Aplidin
Chapter 7
EMERGING THERAPIES FOR MYELODYSPLASTIC SYNDROMES
7.1. Amgen?s Nplate (Romiplostim)
7.2. Celgene?s REVLIMID
7.3. Cyclacel Pharmaceuticals? Sapacitabine
7.4. Medac GmbH?s Treosulfan
7.5. Onconova Therapeutics? ESTYBON (Rigosertib); SymBio Pharmaceuticals? Rigosertib
7.6. Telik?s TELINTRA
Chapter 8
EMERGING THERAPIES FOR MYELOPROLIFERATIVE DISEASES
8.1. Celgene?s Actimid
8.2. Geron?s Imetelstat
8.3. Gilead Sciences? GS 6624
8.4. Incyte?s and Novartis? Ruxolitinib
8.5. Infinity Pharmaceuticals? IPI-926
8.6. Sanofi?s SAR302503
8.7. YM Biosciences? CYT387
Chapter 9
BUSINESS CONSIDERATIONS
9.1. Current Sales of Drugs for Treatment of Hematological Cancers
9.2. Personalized Medicine in the Field of Hematological Cancers
9.3. Selected Challenges and Hurdles Being Faced by Companies in the Field of Hematological Cancers
Chapter 10
EXPERT INTERVIEWS
References
Appendix: Selected Companies Developing Drugs for Hematological Cancers (General)
Company Index
TABLES
?
Incoming search terms:
- ceplene (1)
- imetelstat market blockbuster 2012 (1)
- vosaroxin patient blog (1)
Related posts:
- Clinical Trials Recruitment in Orphan Diseases ? Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
- Multitargeted Therapies: Promiscuous Drugs and Combination Therapies
- Gallbladder Cancer Therapeutics ? Pipeline Assessment and Market Forecasts to 2018
- Biomarker Technology Platforms for Cancer Diagnoses and Therapies
- Emerging Drug Delivery Technologies & Strategies ? Players, Pipelines & Partnerships
Category: CHI Healthtech, Healthcare
do not call list sports illustrated westminster dog show 2012 words with friends words with friends phlebotomy survivor
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.